Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke

Jonathan Morena; Casey May; Tamara Strohm

doi:10.1016/j.jstrokecerebrovasdis.2020.104865

Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke

J Stroke Cerebrovasc Dis. 2020 Jul;29(7):104865. doi: 10.1016/j.jstrokecerebrovasdis.2020.104865. Epub 2020 May 11.

Authors

Jonathan Morena¹, Casey May², Tamara Strohm³

Affiliations

¹ Department of Neurology, The Ohio State University, 395 W 12th Ave #7, Columbus, OH 43210, USA. Electronic address: Jonathan.Morena@osumc.edu.
² Department of Pharmacy, The Ohio State University, Columbus, OH, USA. Electronic address: Casey.May@osumc.edu.
³ Department of Neurology, The Ohio State University, 395 W 12th Ave #7, Columbus, OH 43210, USA. Electronic address: Tamara.Strohm@osumc.edu.

PMID: 32404288
DOI: 10.1016/j.jstrokecerebrovasdis.2020.104865

Abstract

We present what may be the first case report of acute thrombocytopenia after tissue plasminogen activator (tPA) in the setting of stroke. Early fibrinogen degradation coagulopathy (EFDC) after tPA has been described in the past and acute thrombocytopenia may fall into this spectrum. Further studies are needed to evaluate the bleeding and mortality risk associated with thrombocytopenia after tPA.

Keywords: Coagulopathy; Complications; Thrombocytopenia; Tissue plasminogen activator.

Publication types

Case Reports

MeSH terms

Acute Disease
Aged, 80 and over
Blood Platelets*
Female
Fibrinolytic Agents / administration & dosage
Fibrinolytic Agents / adverse effects*
Humans
Platelet Count
Stroke / diagnosis
Stroke / drug therapy*
Thrombocytopenia / blood
Thrombocytopenia / diagnosis
Thrombocytopenia / etiology*
Thrombolytic Therapy / adverse effects*
Time Factors
Tissue Plasminogen Activator / administration & dosage
Tissue Plasminogen Activator / adverse effects*
Treatment Outcome

Substances

Fibrinolytic Agents
Tissue Plasminogen Activator